Non-insulin-dependent diabetes mellitus (NIDDM) is characterised by an increase in basal glucose concentrations, upon which are superimposed exaggerated postprandial glucose excursions, induced by a combination of beta-cell dysfunction and impaired insulin sensitivity [1] . Sulphonylurea therapy improves beta-cell function approximately twofold [2] , but the marked insulin secretory defect persists in most patients, so that the enhancement is usually insufficient to maintain near-normal glucose concentrations, Diabetologia (1997) 40: 205-211 Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM Summary The gut hormone, glucagon-like peptide-1 (GLP-1) is a potent insulin secretogogue with potential as a therapy for non-insulin-dependent diabetes mellitus (NIDDM). GLP-1 has been shown to reduce glucose concentrations, both basally, and, independently, in response to a single meal. For it to be an effective treatment, it would need to be administered as a long-acting therapy, but this might not be feasible due to the profound delay in gastric emptying induced by GLP-1. In order to assess the feasibility and efficacy of continuous administration of GLP-1 in NIDDM, we determined the effects of continuous intravenous infusion of GLP-1 (7-36) amide, from 22.00-17.00 hours, on glucose and insulin concentrations overnight and in response to three standard meals, in eight subjects with NIDDM. These were compared with responses to 0.9 % NaCl infusion and responses in six non-diabetic control subjects who were not receiving GLP-1. Effects on beta-cell function were assessed in the basal state using homeostasis model assessment (HOMA) and in the postprandial state by dividing incremental insulin responses to breakfast by incremental glucose responses. To assess possible clinical benefit from priming of beta cells by GLP-1 given overnight only, a third study assessed the effect of GLP-1 given from 22.00-07.30 hours on subsequent glucose responses the next day. Continuous GLP-1 infusion markedly reduced overnight glucose concentrations (mean from 24.00-08.00 hours) from median (range) 7.8 (6.1-13.8) to 5.1 (4.0-9.2) mmol/l (p < 0.02), not significantly different from control subjects, 5.6 (5.0-5.8) mmol/l. Daytime glucose concentrations (mean from 08.00-17.00 hours) were reduced from 11.0 (9.3-16.4) to 7.6 (4.9-11.5) mmol/l (p < 0.02), not significantly different from control subjects, 6.7 (6.5-7.0) mmol/l. GLP-1 improved beta-cell function in the basal state from 62 (13-102) to 116 (46-180) %b (p < 0.02) and following breakfast from 57 (19-185) to 113 (31-494) pmol/mmol (p < 0.02). GLP-1 only given overnight did not improve the glucose responses to meals the next day. In conclusion, continuous infusion of GLP-1 markedly reduced diurnal glucose concentrations, suggesting that continuous GLP-1 administration may be a useful therapy in NIDDM. [Diabetologia (1997) 40: 205-211] 
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either basally [3] or after meals [4] . Other agents which can improve beta-cell function are required.
The beta-cell insulin response to a given increase in plasma glucose is greater when the glucose has been given orally rather than intravenously [5] . This is due in part to secretion of gut hormones, termed incretins, which potentiate glucose-induced insulin secretion [6] . The peptides which appear to make the greatest contribution are gastric inhibitory peptide and specific truncated forms of glucagon-like peptide-1 (GLP-1) [7, 8] . The latter are derived from the pre-proglucagon gene by tissue-specific post-translational processing [9] and are secreted from the L-cells of the distal ileum and colon. The incretin forms of this peptide are GLP-1 (7-37) and GLP-1 (7-36) amide, the latter being the naturally occurring form in humans [10] . For ease of expression, we will refer to these active truncated peptides as GLP-1.
GLP-1 is a potent stimulator of insulin secretion in the perfused pancreas [11] [12] [13] . A 4-h intravenous infusion of GLP-1 has been shown to reduce fasting glucose concentrations to near-normal in NIDDM subjects with poor glycaemic control on maximal tablet therapy [14] and a 10-h, overnight infusion in NIDDM subjects, maintained near-normal glucose concentrations overnight [15] . Continuous intravenous infusion of GLP-1 in NIDDM subjects improved the impaired basal beta-cell function and the impaired first-and second-phase insulin responses to intravenous glucose into the normal range [15] . This global improvement in beta-cell function suggested that, in addition to reducing overnight/fasting glucose concentrations, continuous stimulation by GLP-1 may also reduce the exaggerated postprandial glucose excursions of NIDDM. Administration of GLP-1 before a single meal by a brief intravenous infusion [16] or by subcutaneous injections [17] , has been shown to decrease postprandial glucose excursions, but to have no effect on subsequent basal glucose concentrations. Thus, previous studies have shown efficacy of GLP-1 in the basal state and, independently, during a single meal, but in order for it to be an effective treatment for reduction of both overnight and daytime glucose concentrations, it would need to be administered as a long-acting therapy, in the basal state and through meals. Giving GLP-1 through several consecutive meals, however, may not be possible as GLP-1 profoundly delays gastric emptying [18, 19] .
This study was performed in order to determine the feasibility and efficacy of continuous administration of GLP-1 in NIDDM, by assessing the effect of a 19-h, continuous intravenous infusion of GLP-1 on glucose concentrations overnight and in response to three standard meals in NIDDM subjects.
In vitro studies have shown that prior exposure of beta cells to GLP-1 has a priming effect on their subsequent insulin response to glucose [20, 21] . Since this suggested that overnight administration of GLP-1 might sufficiently prime the beta cells and that the clinical benefit would persist during the next day, we also evaluated whether an overnight GLP-1 infusion, that was stopped before breakfast, would maintain improved glucose control during the day. Thus, if continuous administration of GLP-1 was not feasible because of profound delay in gastric emptying through meals, overnight therapy -potentially with an intermediate acting injection of GLP-1-might be a feasible option, if continued benefit the next day could also be demonstrated.
Subjects and methods
Subjects. Eight patients with NIDDM, who were maintaining their usual body weight, were studied, together with six non-diabetic control subjects of similar age and level of obesity. Seven of the eight diabetic subjects completed the part of the study where GLP-1 was given continuously for 19 h and were included in the main analyses. Their characteristics, together with those of the control subjects, are shown in Table 1 . The diabetic subjects had all met World Health Organisation criteria for NIDDM at diagnosis and had been treated with either diet alone (n = 4), or with additional sulphonylureas (n = 3). The oral hypoglycaemic agents were discontinued at least 3 weeks before entry into the study. The non-diabetic control subjects all had normal fasting glucose values and had normal glucose responses to a standard meal-tolerance test. The study was approved by the Central Oxford Research and Ethics Committee and all subjects gave written informed consent.
Protocol. The diabetic subjects were admitted to an investigation unit at 21.00 hours on three occasions, having finished their last meal by 19.00 hours. Two intravenous cannulae were inserted under local anaesthetic. Blood samples were taken from the distal forearm, which was heated with a thermoregulated blanket to arterialize venous blood. At 22.00 hours, after having drawn preinfusion blood samples, intravenous infusions of GLP-1 (7-36) amide (Bachem, Calif., USA) or placebo (0.9 % NaCl, saline), both containing 0.45 % human serum albumin (Bio-Products Laboratory, Elstree, Herts, UK), were commenced. Infusions were continued until 17.00 hours the following day. Saline infusion was given throughout one visit and GLP-1, given at a rate of 1.2 pmol ⋅ kg
, was infused on two visits, once throughout and once stopping at 07.30 hours, with saline infusion for the remainder of that day. The infusions were given in randomised order. On all three nights, blood was drawn hourly for laboratory plasma glucose measurement and 2 hourly for insulin. The following day, subjects received three standard meals. Breakfast (397 kcal, 57.1 g carbohydrate) was given at 08.00 hours; lunch Values are mean ± SD (609 kcal, 70.4 g carbohydrate) at 12.00 hours and afternoon snack (199 kcal, 26.4 g carbohydrate) at 15.00 hours. Blood samples were taken intermittently throughout the day. Nondiabetic control subjects attended on one occasion and underwent the identical overnight and daytime protocol, without GLP-1.
Biochemical assays. Blood samples were drawn into plastic tubes containing heparin and were immediately placed on ice. The samples were centrifuged at 4°C. Plasma glucose concentrations were measured that day and plasma samples for insulin stored at − 20°C. Plasma glucose was determined by a hexokinase method on a Cobas MIRA discrete analyser (Roche Diagnostica, Welwyn Garden City, Herts, UK). Plasma immunoreactive insulin was determined by double antibody radioimmunoassay [22] . Inter-assay coefficient of variation (C. V.) was 3.3 % at 300 pmol/l. 
Results
Six of the eight subjects completed all three parts of the study. Four of these subjects had no side-effects and two had mild nausea at some stage during the night when GLP-1 was given, which settled spontaneously.
In the study when GLP-1 was continued throughout the day, the seventh subject experienced nausea in the night, continuing through breakfast, requiring discontinuation of the infusion. This subject was not included in the data analyses. The eighth subject had no symptoms during the study where GLP-1 was given throughout, but unexpectedly developed nausea and vomiting during the visit where GLP-1 was to be given overnight only, requiring its discontinuation.
Overnight and daytime glucose concentrations in the control subjects and the seven diabetic subjects on the continued GLP-1 and saline infusion study days are shown in Figure 1 a. The diabetic subjects on saline had the expected hyperglycaemia due to a combination of raised basal glucose concentrations and exaggerated postprandial glucose excursions. During the GLP-1 infusion, glucose concentrations fell rapidly over the first 2 h and marked reduction of both overnight and daytime glucose concentrations, to near-normal levels, was maintained. Mean overnight and daytime glucose concentrations in each individual are shown in Figure 2 . On the saline infusion, the diabetic subjects had overnight glucose concentrations (time-averaged mean from 24.00 to 08.00 hours in each individual) of median (range), 7.8 (6.1-13.8) mmol/l, higher than control subjects, 5.6 (5.0-5.8) mmol/l (p < 0.001) (Fig. 2 a) . Continuous GLP-1 infusion reduced this to 5.1 (4.0-9.2) mmol/l (p < 0.02, compared with saline), not significantly different from control subjects. Glucose concentrations remained constant from 24.00 hours to 08.00 hours in both the diabetic subjects on the saline infusion and the control group, but during GLP-1 infusion, rose at a rate of 0.2 mmol ⋅ l
( Fig. 1 a) . 
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Daytime glucose concentrations (time-averaged mean from 08.00 to 17.00 hours in each individual) were raised in the diabetic subjects receiving saline infusion, 11.0 (9.3-16.4) mmol/l, compared with control subjects, 6.7 (6.5-7.0) mmol/l (p < 0.001) (Fig. 2 b) . Continuous GLP-1 infusion reduced this to 7.6 (4.9-11.5) mmol/l (p < 0.02, compared with saline), not significantly different from control subjects. In addition to reduction in baseline glucose concentrations, the incremental postprandial glucose concentrations were markedly reduced by GLP-1 from 2.7 (1.0-3.6) mmol/l on saline infusion to 0.8 (0.5-1.9) mmol/l (p < 0.02), not significantly different from control subjects, 1.1 (0.4-2.3) mmol/l.
In the seven subjects who completed the overnight GLP-1 study, when the infusion was discontinued 30 min before breakfast, the glucose concentrations rose within the 30 min before breakfast and, during the day, returned to the levels recorded with saline infusion (Fig. 1 b) .
Overnight and daytime insulin concentrations in the control subjects and the diabetic subjects on the continued GLP-1 and saline infusion studies are shown in Figure 3 , with the expected daytime insulin levels lower in the diabetic subjects than the control subjects. Figure 4 shows measures of basal and postprandial beta-cell function in each individual. At 08.00 hours, the diabetic group on the saline infusion visit had basal beta-cell function (assessed by HOMA), of median (range), 62 (13-102) %b, lower than in the similarly obese control subjects, 106 (93-125) %b (p < 0.005) (Fig. 4 a) . With continuous infusion of GLP-1, basal beta-cell function in the diabetic group improved to 116 (46-180) %b (p < 0.02, compared with saline), not significantly different from control subjects. The insulin response relative to the glycaemic stimulus postprandially was assessed in each individual by the mean insulin increment divided by the mean glucose increment over the 3 h after breakfast. The responses in the diabetic subjects on saline infusion, 57 (19-185) pmol/mmol, were lower than those of the control subjects, 268 (105-634) pmol/mmol (p < 0.001) (Fig. 4 b) . Continuous GLP-1 in the diabetic subjects improved this to 113 (31-494) pmol/mmol (p < 0.02, compared with saline). Although this was not significantly different from control subjects (p = 0.051), most subjects remained at the lower end of, or below, the control range (Fig. 4 b) .
Insulin sensitivity determined at 08.00 hours, by HOMA, was similar in the diabetic subjects during saline infusion and control subjects, 32 (11-71) %S and 41 (25-75) %S, respectively, and in the diabetic subjects, did not change significantly in response to GLP-1 infusion, 19 (15-95) %S.
Discussion
This study showed that continuous infusion of GLP-1 markedly improved both overnight and daytime glucose concentrations in subjects with NIDDM, without delayed gastric emptying causing side-effects after several consecutive meals. This suggests that continuous administration of GLP-1, by long-acting subcutaneous formulation or other means, would be a feasible and efficacious therapy for NIDDM. The overnight plasma insulin concentrations during the GLP-1 infusion were similar to those during the saline infusion. A previous study of intravenous GLP-1 administration to subjects with NIDDM showed an initial increase in insulin concentrations with GLP-1, which returned to the original concentrations when the plasma glucose approached normal [14] . It is likely that the marked decrease in glucose concentrations over the first 2 h of the GLP-1 infusion in this study was similarly due to an initial increase in insulin concentrations, which was not detected since no measurements were taken until 2 h after commencement of the infusion, by which time the glucose concentrations were already normal. In addition, GLP-1 infusion has been shown to improve acutely insulin-independent glucose disposal [26] and reduce glucagon concentrations [14] and these effects may have also contributed to the initial decrease in glucose concentrations. Lower glucose concentrations were maintained thereafter by GLP-1-induced improvement in beta-cell function (glucose-induced insulin secretion) as shown by similar insulin concentrations during saline and GLP-1 infusions, despite significantly lower glucose concentrations with GLP-1. This improvement in basal beta-cell function was quantified by use of HOMA of the insulin concentrations at 08.00 hours relative to the glucose concentrations [23] and showed that GLP-1 improved basal beta-cell function into the normal range in most subjects.
Postprandial beta-cell function was assessed by the relationship between postprandial insulin and glucose increments. Although the insulin/glucose ratio improved significantly with GLP-1, in most subjects it remained at the lower end of, or below, the control range. Postprandial insulin secretion is influenced by a variety of neuroendocrine and other factors, such as rate of gastric emptying, which do not play a major role in control of basal insulin secretion. Although GLP-1 markedly improved the impaired basal betacell function of subjects with NIDDM, the impaired postprandial beta-cell function was only slightly improved, suggesting that there are defects in control of postprandial insulin secretion in NIDDM for which GLP-1 does not compensate. GLP-1 normalised the postprandial glucose increments, despite not normalising postprandial insulin secretion, and its other known effects are likely to have contributed, such as delay in gastric emptying [18, 19] , which may allow the glucose load after meals to be more efficiently handled by the impaired beta cells, and enhancement of insulin-independent glucose disposal [26, 27] .
The study where GLP-1 was given overnight and discontinued before breakfast showed no reduction of glucose concentrations the following day, suggesting that GLP-1 induced priming of beta cells, demonstrated in in vitro studies [20, 21] has little clinical relevance.
In vitro [13, 21, 28 ] and in vivo [14] studies have suggested that the insulinotropic actions of GLP-1 are highly glucose dependent, i. e. greater at raised than normal glucose concentrations, and none of the subjects in this study experienced hypoglycaemia with GLP-1. Two of the eight subjects studied experienced significant side-effects of nausea or vomiting and two experienced mild, transient nausea with GLP-1. The dose of GLP-1 used was empirical and based on our own [15] and other groups' [14] experiences with similar doses. This is the first study to report side-effects with GLP-1 in diabetic subjects, although vomiting has been reported in non-diabetic subjects given very high doses of GLP-1 [29] . GLP-1 
T
, compared with individual non-diabetic control subjects ◊ has binding sites in the rat brain [30, 31] and its effects on gastric emptying and acid secretion could be centrally mediated [30] . The symptoms in this study occurred overnight, but may nevertheless have been due to delayed gastric emptying. It was reassuring, however, that no symptoms occurred after any of the meals, as previous studies have suggested that continuous administration of GLP-1 may not be feasible because of profound inhibition of postprandial gastric emptying [18] . Further studies will reveal whether the overnight side-effects might restrict the clinical use of GLP-1 and whether doses giving lower plasma concentrations of GLP-1 would be similarly effective with less likelihood of symptoms. Additional studies to evaluate whether continuous administration of GLP-1 will be similarly effective in more hyperglycaemic subjects are also required.
The effects of GLP-1 on the beta cell are mediated via a specific GLP-1 receptor [32, 33] that activates adenylate cyclase, resulting in increased cyclic adenosine monophosphate (cAMP) levels. Activation of cAMP-dependent protein kinases, such as protein kinase A, may increase insulin release via a number of mechanisms [21, [34] [35] [36] . A potential problem with supraphysiological doses of GLP-1 is that tachyphylaxis might occur due to down-regulation of its receptors or post-receptor mechanisms. The rise in overnight fasting glucose from 24.00 to 08.00 hours on GLP-1 was greater than the rise on saline or in control subjects, suggesting that GLP-1 may have been losing efficacy overnight. A recently reported study of 1-week infusion of GLP-1 in subjects with NIDDM [37], however, showed similar efficacy on days 1 and 7, suggesting that tachyphylaxis is unlikely to occur with continuous administration of GLP-1.
In conclusion, this study has established, in principle, that GLP-1 given continuously has the ability to reduce both overnight and daytime glucose concentrations in subjects with NIDDM. Continuous infusion of GLP-1 is not a feasible therapy, but continuous administration of GLP-1, given by another route such as a long-acting subcutaneous formulation, may have therapeutic relevance in NIDDM, particularly as GLP-1 gives little risk of hypoglycaemia due to the glucose dependency of its action. 
